Share of Cost, Researchers Discover Master Regulator That Drives Majority Of Lymphoma

Saturday, Dec. 7th 2013 9:00 AM

New Findings Show Inhibiting Powerful Protein with New Agents May Supply Broad Benefit for Lymphoma Patients A soon-to-be-tested class of drug inhibitors were predicted to help a limited number of patients with B-cell lymphomas with mutations affecting the EZH2 protein. However, a research team, led by investigators at Weill Cornell Medical College, now report that these agents may, in fact, help a much broader cross section of lymphoma patients.

Posted on Saturday, Dec. 7th 2013 9:00 AM | by Share of Cost | in Share of Cost | No Comments »

Leave a Reply

You must be logged in to post a comment.